Enzychem’s EC-18 lowers occurrence of oral mucositis in Phase II trial
Join Our Newsletter - Get important industry news and analysis sent to your inbox – sign up to our e-Newsletter here
X

Enzychem’s EC-18 reduces occurrence of oral mucositis in Phase II trial

20 Oct 2021 (Last Updated October 20th, 2021 15:14)

The therapy met the primary and secondary endpoints in the trial in chemoradiation-induced oral mucositis patients.

Enzychem Lifesciences has reported that its lead candidate, EC-18, decreased the duration and occurrence of severe oral mucositis in a Phase II clinical trial in head and neck cancer patients.

A new small molecule oral immunomodulator, EC-18 is being analysed for chemoradiation-induced oral mucositis (CRIOM). It potentially aids in resolving inflammation and quick return to homeostasis.

Carried out in the US, the Phase II trial assessed EC-18 to treat oral mucositis in individuals with concomitant chemo-irradiation for mouth, hypopharynx, oropharynx, and nasopharynx cancers.

The first stage trial enrolled 24 participants, who were randomised to receive either 500mg or 1000mg or 2000mg dose of EC-18 or placebo.

Around 81 subjects were part of stage two, where they were given either a twice-daily dose of 2,000mg EC-18 or a placebo for nearly seven weeks.

Data showed that EC-18 met the primary and secondary goals of efficacy and safety in the trial.

Subjects in the EC-18 arms had a decline in the duration of severe oral mucositis (SOM) through a short-term follow-up period versus the placebo group.

In addition, the oral immunomodulator reduced the occurrence of SOM through the conclusion of radiation treatment by 37.1% as against subjects on placebo.

The SOM occurrence through a short-term follow-up period dropped by 35.1% versus placebo.

In the trial, no serious adverse events (SAE) were observed between placebo and EC-18 arms.

Safety was similar across all groups, with the adverse events (AEs) linked to chemoradiation-associated toxicity.

Enzychem Lifesciences CEO and chairman Ki-Young Sohn said: “We are delighted to announce these positive results from our Phase II US study, which confirm that EC-18 is safe and well-tolerated.

“In addition, EC-18 may have a number of key advantages, including oral route of administration and convenience of use. We are excited to advance this novel candidate into a pivotal study and will also evaluate EC-18 for other radiation-induced inflammatory diseases.”

Based on the latest positive data from the Phase II trial, the company intends to seek breakthrough therapy designation for EC-18 from the US Food and Drug Administration (FDA) this year.

Furthermore, the oral treatment will be advanced to international Phase III trials.